ABO-incompatible heart transplantation: A special case for the A2 donor

G. Y. Ott, Douglas Norman, R. R. Ratkovec, R. E. Hershberger, J. D. Hosenpud, A. Cobanoglu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Limited clinical experience concerning heart transplantation across ABO blood group barriers suggests a high incidence of hyperacute rejection and poor patient outcome. Reported is a case of the short-term survival of an ABO-mismatched cardiac graft without evident adverse immunologic effects. A 41-year-old man with blood type O underwent heart transplantation receiving a blood type A2 donor organ. Cyclosporine-based immunosuppression was augmented with daily plasmapheresis and OKT3 therapy. Circulating anti-A antibodies were reduced quickly and held to a very low level with this regimen. The patient remained hemodynamically stable until retransplantation 4 days later. The explanted heart showed no evidence of cellular infiltrate or antibody deposition. Long-term success with the use of type A2 organs in type O recipients has been shown in select series with other types of solid organ transplants. Although this patient underwent retransplantation early, the lack of rejection phenomena gives evidence that the relatively low antigenicity of the A2 subtype may allow planned heart transplantation across this blood group barrier, either as a bridge or on a permanent basis.

Original languageEnglish (US)
Pages (from-to)504-507
Number of pages4
JournalJournal of Heart and Lung Transplantation
Volume12
Issue number3
StatePublished - 1993

Fingerprint

Heart Transplantation
varespladib methyl
Tissue Donors
Blood Group Antigens
Transplants
Muromonab-CD3
Plasmapheresis
Blood Donors
Immunosuppression
Cyclosporine
Anti-Idiotypic Antibodies
Antibodies
Incidence
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Ott, G. Y., Norman, D., Ratkovec, R. R., Hershberger, R. E., Hosenpud, J. D., & Cobanoglu, A. (1993). ABO-incompatible heart transplantation: A special case for the A2 donor. Journal of Heart and Lung Transplantation, 12(3), 504-507.

ABO-incompatible heart transplantation : A special case for the A2 donor. / Ott, G. Y.; Norman, Douglas; Ratkovec, R. R.; Hershberger, R. E.; Hosenpud, J. D.; Cobanoglu, A.

In: Journal of Heart and Lung Transplantation, Vol. 12, No. 3, 1993, p. 504-507.

Research output: Contribution to journalArticle

Ott, GY, Norman, D, Ratkovec, RR, Hershberger, RE, Hosenpud, JD & Cobanoglu, A 1993, 'ABO-incompatible heart transplantation: A special case for the A2 donor', Journal of Heart and Lung Transplantation, vol. 12, no. 3, pp. 504-507.
Ott GY, Norman D, Ratkovec RR, Hershberger RE, Hosenpud JD, Cobanoglu A. ABO-incompatible heart transplantation: A special case for the A2 donor. Journal of Heart and Lung Transplantation. 1993;12(3):504-507.
Ott, G. Y. ; Norman, Douglas ; Ratkovec, R. R. ; Hershberger, R. E. ; Hosenpud, J. D. ; Cobanoglu, A. / ABO-incompatible heart transplantation : A special case for the A2 donor. In: Journal of Heart and Lung Transplantation. 1993 ; Vol. 12, No. 3. pp. 504-507.
@article{7c343236b07740239d8092e7a63dad29,
title = "ABO-incompatible heart transplantation: A special case for the A2 donor",
abstract = "Limited clinical experience concerning heart transplantation across ABO blood group barriers suggests a high incidence of hyperacute rejection and poor patient outcome. Reported is a case of the short-term survival of an ABO-mismatched cardiac graft without evident adverse immunologic effects. A 41-year-old man with blood type O underwent heart transplantation receiving a blood type A2 donor organ. Cyclosporine-based immunosuppression was augmented with daily plasmapheresis and OKT3 therapy. Circulating anti-A antibodies were reduced quickly and held to a very low level with this regimen. The patient remained hemodynamically stable until retransplantation 4 days later. The explanted heart showed no evidence of cellular infiltrate or antibody deposition. Long-term success with the use of type A2 organs in type O recipients has been shown in select series with other types of solid organ transplants. Although this patient underwent retransplantation early, the lack of rejection phenomena gives evidence that the relatively low antigenicity of the A2 subtype may allow planned heart transplantation across this blood group barrier, either as a bridge or on a permanent basis.",
author = "Ott, {G. Y.} and Douglas Norman and Ratkovec, {R. R.} and Hershberger, {R. E.} and Hosenpud, {J. D.} and A. Cobanoglu",
year = "1993",
language = "English (US)",
volume = "12",
pages = "504--507",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - ABO-incompatible heart transplantation

T2 - A special case for the A2 donor

AU - Ott, G. Y.

AU - Norman, Douglas

AU - Ratkovec, R. R.

AU - Hershberger, R. E.

AU - Hosenpud, J. D.

AU - Cobanoglu, A.

PY - 1993

Y1 - 1993

N2 - Limited clinical experience concerning heart transplantation across ABO blood group barriers suggests a high incidence of hyperacute rejection and poor patient outcome. Reported is a case of the short-term survival of an ABO-mismatched cardiac graft without evident adverse immunologic effects. A 41-year-old man with blood type O underwent heart transplantation receiving a blood type A2 donor organ. Cyclosporine-based immunosuppression was augmented with daily plasmapheresis and OKT3 therapy. Circulating anti-A antibodies were reduced quickly and held to a very low level with this regimen. The patient remained hemodynamically stable until retransplantation 4 days later. The explanted heart showed no evidence of cellular infiltrate or antibody deposition. Long-term success with the use of type A2 organs in type O recipients has been shown in select series with other types of solid organ transplants. Although this patient underwent retransplantation early, the lack of rejection phenomena gives evidence that the relatively low antigenicity of the A2 subtype may allow planned heart transplantation across this blood group barrier, either as a bridge or on a permanent basis.

AB - Limited clinical experience concerning heart transplantation across ABO blood group barriers suggests a high incidence of hyperacute rejection and poor patient outcome. Reported is a case of the short-term survival of an ABO-mismatched cardiac graft without evident adverse immunologic effects. A 41-year-old man with blood type O underwent heart transplantation receiving a blood type A2 donor organ. Cyclosporine-based immunosuppression was augmented with daily plasmapheresis and OKT3 therapy. Circulating anti-A antibodies were reduced quickly and held to a very low level with this regimen. The patient remained hemodynamically stable until retransplantation 4 days later. The explanted heart showed no evidence of cellular infiltrate or antibody deposition. Long-term success with the use of type A2 organs in type O recipients has been shown in select series with other types of solid organ transplants. Although this patient underwent retransplantation early, the lack of rejection phenomena gives evidence that the relatively low antigenicity of the A2 subtype may allow planned heart transplantation across this blood group barrier, either as a bridge or on a permanent basis.

UR - http://www.scopus.com/inward/record.url?scp=0027168274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027168274&partnerID=8YFLogxK

M3 - Article

C2 - 8329427

AN - SCOPUS:0027168274

VL - 12

SP - 504

EP - 507

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 3

ER -